Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(1)
About
Natco Pharma Ltd.
NSE: NATCOPHARM
|
BSE: 524816
|
ISIN: INE987B01026
|
Industry: Pharmaceuticals
US FDA Observation
|
Strong Performer, Under Radar
875.0000
-6.60
(
-0.75
%)
NSE
Jun 20, 2025
15:12 PM
46.61% Fall from 52W High
Volume:
536.2K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Natco Pharma Ltd.
11 Aug 2022
US FDA Observation
875.00
-0.75%
Revlimid leads Q1FY23 performance
Buy:
Natco Pharma Ltd.
by
ICICI Securities Limited
Target: 818
Recommendation
Target
ICICI Securities Limited
Natco Pharma’s (Natco) Q1FY23 performance was ahead of our estimates led by ramp-up in Revlimid.
Natco Pharma Ltd. is trading
above its 50 day SMA
of 853.2
More from Natco Pharma Ltd.
Recommended
Market trades higher, Nestle to consider bonus issue in a board meeting on June 26
Trendlyne Marketwatch |
20 Jun 2025, 02:59PM
Winners and losers of 2025 in global indices | Screener: Nifty outperformers (so far) this year
The Baseline |
19 Jun 2025, 11:24AM
Earnings Call Transcript - Q4FY20 for Natco Pharma
|
18 Jun 2020, 06:25PM